Sorbitol
Baxter Healthcare Corporation
Human Prescription Drug
NDC 0338-0295Sorbitol is a human prescription drug labeled by 'Baxter Healthcare Corporation'. National Drug Code (NDC) number for Sorbitol is 0338-0295. This drug is available in dosage form of Irrigant. The names of the active, medicinal ingredients in Sorbitol drug includes Sorbitol - 30 g/1000mL . The currest status of Sorbitol drug is Active.
Drug Information:
| Drug NDC: | 0338-0295 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Sorbitol |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Prescription Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Sorbitol |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Baxter Healthcare Corporation |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Irrigant |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | SORBITOL - 30 g/1000mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | IRRIGATION
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | NDA |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 30 May, 1980 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | NDA017863 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Baxter Healthcare Corporation
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 313090
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 506T60A25R
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 0338-0295-47 | 3000 mL in 1 BAG (0338-0295-47) | 30 May, 1980 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Product Elements:
Sorbitol sorbitol sorbitol sorbitol water
Indications and Usage:
Indications and usage 3% sorbitol urologic irrigating solution is indicated for use as a urologic irrigating fluid with endoscopic instruments during transurethral procedures requiring distension, irrigation, and lavage of the urinary bladder. it may be used for lavage of an indwelling catheter to maintain patency.
Warnings:
Warnings not for injection. not for use in patients with documented or suspected fructose intolerance. solutions for urologic irrigation must be used with caution in patients with severe cardiopulmonary or renal dysfunction. irrigating fluids used during transurethral prostatectomy have been demonstrated to enter the systemic circulation in relatively large volumes; thus sorbitol irrigating solution must be regarded as a systemic drug. absorption of large amounts of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics. appropriate patient monitoring should be maintained due to the possibility of fluid overload. should fluid overload occur, intensive fluid and electrolyte management is necessary. monitoring of fluid and electrolyte levels beyond the acute phase may be considered due to the possibility of delayed fluid absorption. (see adverse reactions, post-marketing experience) hyperglycemia from metabolism of absorbed sorbitol may occur in patients wi
Read more...th diabetes mellitus. the contents of an opened container should be used promptly to minimize the possibility of bacterial growth or pyrogen formation. discard the unused portion of irrigating solution since no antimicrobial agent has been added.
Dosage and Administration:
Dosage and administration the volume of solution needed will vary with the nature and duration of the urologic procedure. if desired, warm in overwrap to near body temperature in a water bath or oven heated to not more than 45°c. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Contraindications:
Contraindications anuria.
Adverse Reactions:
Adverse reactions life threatening adverse reactions with intravenous sorbitol infusions have been reported in patients with fructose intolerance. the literature reports occasional adverse reactions for intravenous sorbitol infusions. these include disturbances such as acidosis, electrolyte loss, marked diuresis, urinary retention, edema, dryness of mouth and thirst, and dehydration; cardiovascular/pulmonary disorders such as pulmonary congestion, hypotension, tachycardia, angina-like pains, and other general reactions such as blurred vision, convulsions, nausea, vomiting, diarrhea, rhinitis, chills, vertigo, and backache. allergic reactions reported to occur from sorbitol include urticaria. should adverse reactions occur, discontinue the irrigant and reevaluate the clinical status of the patient. post-marketing experience following off-label use of 3% sorbitol urologic irrigating solution for hysteroscopic procedures in women, life-threatening adverse events related to fluid overload
Read more...have been reported.
Use in Pregnancy:
Pregnancy teratogenic effects animal reproduction studies have not been conducted with 3% sorbitol urologic irrigating solution. it is not known whether 3% sorbitol urologic irrigating solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. 3% sorbitol urologic irrigating solution should be given to a pregnant woman only if clearly needed.
Pediatric Use:
Pediatric use safety and effectiveness in pediatric patients have not been established.
Geriatric Use:
Geriatric use clinical studies of irrigation solutions did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from other younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. do not administer unless the solution is clear and the seal is intact.
Description:
Description 3% sorbitol urologic irrigating solution is a sterile, nonpyrogenic, nonhemolytic, electrically nonconductive solution in a single dose uromatic plastic container for use as a urologic irrigating solution. each liter contains 30 g sorbitol in water for injection. ph 5.0 (4.5 to 6.5). osmolarity 165 mosmol/l (calc.). no antimicrobial agent has been added. sorbitol is a reduced form of dextrose and is designated chemically as d-glucitol, the uromatic plastic container is fabricated from a specially formulated polyvinyl chloride (pl 146 plastic). the amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (dehp), up to 5 parts per million; however, the safety of the plastic has been confirmed in tests in animals according to usp biological tests for plastic containers as well as by tissue culture toxicity studies. sorbitol structural formula
Clinical Pharmacology:
Clinical pharmacology 3% sorbitol urologic irrigating solution is useful as an irrigating fluid for the urinary bladder because the sorbitol solution is nonhemolytic, electrically nonconductive, and provides a high degree of visibility for urologic procedures requiring endoscopy. during transurethral surgical procedures, the solution acts as a lavage for removing blood and tissue fragments. it is also useful as an irrigating fluid to maintain the patency of an indwelling catheter in the immediate postoperative period. if absorbed either intravascularly or extravascularly during transurethral resections, the sorbitol will be either metabolized to carbon dioxide and water via the fructose pathway, or excreted by a normally functioning kidney.
How Supplied:
How supplied 3% sorbitol urologic irrigating solution in uromatic plastic containers is available as follows: 2b7357 3000ml ndc 0338-0295-47 exposure of pharmaceutical products to heat should be minimized. avoid excessive heat. it is recommended the product be stored at room temperature (25°c); brief exposure up to 40°c does not adversely affect the product.
Package Label Principal Display Panel:
Principal display panel - packaging labeling container label container label lot exp 3000 ml 2b7357 ndc 0338-0295-47 not for injection 3% sorbitol urologic irrigating solution each 100 ml contains 3 g sorbitol no antimicrobial agent has been added ph 5.0 (4.5 to 6.5) hypotonic osmolarity 165 mosmol/l (calc) sterile nonpyrogenic single dose container do not use unless solution is clear discard unused portion hypotonic solution for bladder irrigation in connection with cystoscopic examination and urological surgical procedures see direction sheet cautions squeeze and inspect inner bag which maintains product sterility discard if leaks are found rx only store unit in moisture barrier overwrap at room temperature (25°c) until ready to use avoid excessive heat see insert uromatic container pl 146 plastic baxter uromatic and pl 146 are trademarks of baxter international inc baxter logo baxter healthcare corporation deerfield il 60015 usa made in usa for product information 1-800-933-0303 carton label carton label 2b7357 4-3000 ml uromatic containers 3% sorbitol urologic irrigating solution exp xxxxx secondary bar code (17) yymm00 (10) xxxxx lot xxxxx primary bar code (01) 50303380295475 sorbitol representative container label sorbitol representative carton label